Human herpes virus 6 reactivation following autologous hematopoietic cell transplantation–a single-center experience

Liat Shargian-Alon; Dafna Yahav; Uri Rozovski; Sara Dovrat; Irina Amitai; Michal Sela-Navon; Oren Pasvolsky; Pia Raanani; Moshe Yeshurun

doi:10.1080/10428194.2019.1576869

Human herpes virus 6 reactivation following autologous hematopoietic cell transplantation–a single-center experience

Liat Shargian-Alon, Dafna Yahav, Uri Rozovski, Sara Dovrat, Irina Amitai, Michal Sela-Navon, Oren Pasvolsky, Pia Raanani, Moshe Yeshurun

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Data regarding presentation and management of human herpes virus 6 (HHV-6) reactivation among autologous hematopoietic cell transplantation (HCT) recipients are limited. We retrospectively reviewed medical charts of all autologous HCT patients tested for HHV-6 reactivation due to suspected clinical presentation between 1/2012 and 8/2017. Among 328 autologous HCT recipients, 44 patients were tested for HHV-6 reactivation. Thirty patients tested positive; 29 (97%) had sustained fever, six (20%) had rash and four (13%) had pneumonia. Median C-reactive protein was significantly lower in HHV-6 positive patients compared to negative patients (3.6 (range, 0.4–11) vs. 9.6 (range, 3.2–30) mg/dL, respectively, p =.004). Ganciclovir formulations were administrated in 29 (97%) patients with median time to fever resolution of one (range, 1–2) day. HHV-6 should be considered as an important cause of post engraftment fever in autologous HCT. Larger studies are warranted to evaluate incidence of HHV-6 reactivation and optimal treatment regimen.

Original language	English (US)
Pages (from-to)	2230-2236
Number of pages	7
Journal	Leukemia and Lymphoma
Volume	60
Issue number	9
DOIs	https://doi.org/10.1080/10428194.2019.1576869
State	Published - Jul 29 2019
Externally published	Yes

Keywords

Autologous
HHV-6
human herpes virus 6
transplantation

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2019.1576869

Cite this

@article{fdb9ce865b5d4c899194cbaaead3cc0a,

title = "Human herpes virus 6 reactivation following autologous hematopoietic cell transplantation–a single-center experience",

abstract = "Data regarding presentation and management of human herpes virus 6 (HHV-6) reactivation among autologous hematopoietic cell transplantation (HCT) recipients are limited. We retrospectively reviewed medical charts of all autologous HCT patients tested for HHV-6 reactivation due to suspected clinical presentation between 1/2012 and 8/2017. Among 328 autologous HCT recipients, 44 patients were tested for HHV-6 reactivation. Thirty patients tested positive; 29 (97%) had sustained fever, six (20%) had rash and four (13%) had pneumonia. Median C-reactive protein was significantly lower in HHV-6 positive patients compared to negative patients (3.6 (range, 0.4–11) vs. 9.6 (range, 3.2–30) mg/dL, respectively, p =.004). Ganciclovir formulations were administrated in 29 (97%) patients with median time to fever resolution of one (range, 1–2) day. HHV-6 should be considered as an important cause of post engraftment fever in autologous HCT. Larger studies are warranted to evaluate incidence of HHV-6 reactivation and optimal treatment regimen.",

keywords = "Autologous, HHV-6, human herpes virus 6, transplantation",

author = "Liat Shargian-Alon and Dafna Yahav and Uri Rozovski and Sara Dovrat and Irina Amitai and Michal Sela-Navon and Oren Pasvolsky and Pia Raanani and Moshe Yeshurun",

note = "Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2019",

month = jul,

day = "29",

doi = "10.1080/10428194.2019.1576869",

language = "English (US)",

volume = "60",

pages = "2230--2236",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "9",

}

TY - JOUR

T1 - Human herpes virus 6 reactivation following autologous hematopoietic cell transplantation–a single-center experience

AU - Shargian-Alon, Liat

AU - Yahav, Dafna

AU - Rozovski, Uri

AU - Dovrat, Sara

AU - Amitai, Irina

AU - Sela-Navon, Michal

AU - Pasvolsky, Oren

AU - Raanani, Pia

AU - Yeshurun, Moshe

PY - 2019/7/29

Y1 - 2019/7/29

N2 - Data regarding presentation and management of human herpes virus 6 (HHV-6) reactivation among autologous hematopoietic cell transplantation (HCT) recipients are limited. We retrospectively reviewed medical charts of all autologous HCT patients tested for HHV-6 reactivation due to suspected clinical presentation between 1/2012 and 8/2017. Among 328 autologous HCT recipients, 44 patients were tested for HHV-6 reactivation. Thirty patients tested positive; 29 (97%) had sustained fever, six (20%) had rash and four (13%) had pneumonia. Median C-reactive protein was significantly lower in HHV-6 positive patients compared to negative patients (3.6 (range, 0.4–11) vs. 9.6 (range, 3.2–30) mg/dL, respectively, p =.004). Ganciclovir formulations were administrated in 29 (97%) patients with median time to fever resolution of one (range, 1–2) day. HHV-6 should be considered as an important cause of post engraftment fever in autologous HCT. Larger studies are warranted to evaluate incidence of HHV-6 reactivation and optimal treatment regimen.

AB - Data regarding presentation and management of human herpes virus 6 (HHV-6) reactivation among autologous hematopoietic cell transplantation (HCT) recipients are limited. We retrospectively reviewed medical charts of all autologous HCT patients tested for HHV-6 reactivation due to suspected clinical presentation between 1/2012 and 8/2017. Among 328 autologous HCT recipients, 44 patients were tested for HHV-6 reactivation. Thirty patients tested positive; 29 (97%) had sustained fever, six (20%) had rash and four (13%) had pneumonia. Median C-reactive protein was significantly lower in HHV-6 positive patients compared to negative patients (3.6 (range, 0.4–11) vs. 9.6 (range, 3.2–30) mg/dL, respectively, p =.004). Ganciclovir formulations were administrated in 29 (97%) patients with median time to fever resolution of one (range, 1–2) day. HHV-6 should be considered as an important cause of post engraftment fever in autologous HCT. Larger studies are warranted to evaluate incidence of HHV-6 reactivation and optimal treatment regimen.

KW - Autologous

KW - HHV-6

KW - human herpes virus 6

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=85072711858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072711858&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1576869

DO - 10.1080/10428194.2019.1576869

M3 - Article

C2 - 30773083

AN - SCOPUS:85072711858

SN - 1042-8194

VL - 60

SP - 2230

EP - 2236

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 9

ER -

Human herpes virus 6 reactivation following autologous hematopoietic cell transplantation–a single-center experience

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this